I124-trastuzumab undergoes preferential uptake in HER2-positive tumors relative to HER2-negative ones, allowing for visualization of HER2 positivity in both primary and metastatic lesions in gastric cancer patients using PET imaging [136] (Figure 5). The gene discussed is ERBB2; the disease is gastric cancer.